News and Trends 4 Feb 2020 Swiss Biotech Raises €16M to Treat Autism Spectrum Disorder …US private equity investors. The Swiss company will use the money to progress its lead candidate treatment for autism spectrum disorder into a phase Ib clinical trial this year. The… February 4, 2020 - 2 minutesmins - By Jonathan Smith Share WhatsApp Twitter Linkedin Email
News and Trends 23 Jan 2019 Update: The FDA Green-lights Clinical Trials for Huntington’s Disease Gene Therapy …the US in late 2019. Published on 23/01/2018: The EMA has given uniQure’s gene therapy candidate for Huntington’s disease Orphan Medicinal Product Designation, which the company hopes to move into… January 23, 2019 - 3 minutesmins - By Alex Dale Share WhatsApp Twitter Linkedin Email
More News! 20 Dec 2018 Cambridge Company Raises €20M for Potential First in Lung Disease …until its acquisition in 2017, had a big phase III failure with a drug candidate for the same condition. The lead candidate of Morphogen-IX is a protein, called bone morphogenetic… December 20, 2018 - 1 minutemin - By Clara Rodríguez Fernández Share WhatsApp Twitter Linkedin Email
News and Trends 28 Jul 2020 Record Series A for Italian Biotech Funds Autoimmune Therapy Italian biotech Enthera raised €28M in Series A funding to develop its drug candidate for type 1 diabetes and inflammatory bowel disease and take it to human trials. Enthera was… July 28, 2020 - 3 minutesmins - By Helen Albert Share WhatsApp Twitter Linkedin Email
News and Trends 22 May 2020 Phase II Fail Ends Swiss-US Drug for Rare Kidney Disease …Swiss collaborator Vifor Pharma to drop it for this indication. Topline results from the phase II trial showed that 12 weeks of treatment with the drug candidate did not decrease… May 22, 2020 - 2 minutesmins - By Anita Chakraverty Share WhatsApp Twitter Linkedin Email
Best in Biotech 12 Jun 2023 Six advancements in Alzheimer’s research over the past year …have advanced as well. For the treatment of Alzheimer’s, lecanemab, a monoclonal antibody that targets amyloid plaques, was developed by Japanese pharmaceutical Eisai in collaboration with American biopharma Biogen. It… June 12, 2023 - 12 minutesmins - By Roohi Mariam Peter Share WhatsApp Twitter Linkedin Email
News and Trends 3 Jan 2018 What Are Clinical Trials and Why Do We Do Them? …new drug will be tested in humans, giving us the chance to find out exactly how it interacts with the body and whether it is any good. The candidate will… January 3, 2018 - 6 minutesmins - By Alex Dale Share WhatsApp Twitter Linkedin Email
News and Trends 6 Jan 2023 BioNTech partnering with UK Government on personalized mRNA cancer immunotherapies …UK as one of the company’s key markets. As part of the MoU, BioNTech and the UK Government plan to accelerate trial site and patient recruitment for clinical candidates of… January 6, 2023 - 4 minutesmins - By Jim Cornall Share WhatsApp Twitter Linkedin Email
News and Trends 11 Aug 2022 Synlogic gets Ginkgo Bioworks’ help to launch T. rex inspired synthetic biotic for gout Synlogic, Inc. has announced a new drug candidate for the treatment of gout developed in partnership with Ginkgo Bioworks. The new candidate, SYNB2081, is a synthetic biotic and is the… August 11, 2022 - 2 minutesmins - By Jim Cornall Share WhatsApp Twitter Linkedin Email
Best in Biotech 10 Oct 2024 12 biotech unicorns revolutionizing the future of healthcare …understanding to inform future discovery. Part of Xaira’s team includes researchers who developed models for protein and antibody design called RFdiffusion and RFantibody in Baker’s lab. The company will use… October 10, 2024 - 11 minutesmins - By Willow Shah-Neville Share WhatsApp Twitter Linkedin Email
News and Trends 3 Jun 2020 What Did European Oncology Players Offer at ASCO 2020? …blood cancer and solid tumors. The candidate that Autolus presented, called AUTO3, is designed to hit two targets at once and make it harder for blood cancer to relapse than… June 3, 2020 - 10 minutesmins - By Jonathan Smith Share WhatsApp Twitter Linkedin Email
Best in Biotech 9 Jul 2024 The 7 biotech companies in Portugal you should know about in 2024 …amyloidosis. This disease is caused by a mutation that leads the protein transthyretin to build up, causing progressive degeneration of multiple organs and tissues. BSIM’s most advanced drug candidate, currently… July 9, 2024 - 7 minutesmins - By Willow Shah-Neville Share WhatsApp Twitter Linkedin Email